Form 4: Cyclo Therapeutics Director Markus Sieger Acquires Shares in Lieu of Cash Compensation

Director Markus Sieger of Cyclo Therapeutics acquired 35,022 shares of common stock in lieu of cash compensation for the third quarter of 2024.

Summary

• Markus Sieger, a director at Cyclo Therapeutics, acquired 35,022 shares of common stock on November 15, 2024.
• These shares were granted in lieu of cash compensation for his services as a director during the third quarter of 2024.
• The share price used to calculate the number of shares was $0.66 per share, based on the closing price on November 14, 2024.
• Following this transaction, Mr. Sieger directly owns 382,122 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of a director receiving stock compensation, which is generally viewed positively as it aligns interests with shareholders. There are no negative implications.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of shares in lieu of cash compensation can be seen as a positive for the company's cash flow.

Industry Context

This is a standard transaction for a director receiving compensation in the form of company stock, which is common practice in publicly traded companies.

Comparison to Industry Standards

• It is common for directors of publicly traded companies to receive a portion of their compensation in the form of company stock.
• This practice aligns with industry standards for aligning director interests with shareholder interests.
• Many companies, such as those in the biotechnology sector, use stock grants as part of their compensation packages to conserve cash.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with those of shareholders.
• The use of stock instead of cash for compensation can be seen as a positive for the company's cash position.

Key Dates

Keywords

Cyclo Therapeutics, Director, Share Acquisition, Stock Grant, Compensation, Form 4, Insider Trading